Trial reportJPEN. Journal of parenteral and enteral nutrition2017
Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome.
Trial report in JPEN. Journal of parenteral and enteral nutrition, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome
A Study of the Safety and Efficacy of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)
A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome
A Long-Term, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition Dependent Short Bowel Syndrome
A One-Year, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition-dependent Short Bowel Syndrome Who Completed Study CL0600-021
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis.Nutrients · 2022Pooled it
- Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026Trial
- Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study.Pediatrics international : official journal of the Japan Pediatric SocietyTrial
- Qualitative Research for the Development of Three New Quality of Life and Treatment Impact Questionnaires for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF).Digestive diseases and sciences · 2026Article
- Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina.World journal of gastrointestinal pharmacology and therapeutics · 2025Article
- Intestinal-Failure-Associated Liver Disease: Beyond Parenteral Nutrition.Biomolecules · 2025Review
- Chronic Intestinal Failure and Short Bowel Syndrome in Adults: The State of the Art.GE Portuguese journal of gastroenterology · 2024Review
- Home Parenteral Support in Chronic Intestinal Failure-First Results from a Pioneer Portuguese Intestinal Failure Center.Nutrients · 2024Article
- Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals.Nutrients · 2024Article
- From intestinal failure to transplantation: Review on the current need for transplant indications under multidisciplinary transplant programs worldwide.Pediatric transplantation · 2024Review
- Evaluation of the Effectiveness of Teduglutide Treatment in Patients with Short Bowel Syndrome in Slovakia-Multicenter Real-World Study.Journal of clinical medicine · 2024Article
- Current Insights Regarding Intestinal Failure-Associated Liver Disease (IFALD): A Narrative Review.Nutrients · 2023Review
- Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells.Advanced pharmaceutical bulletin · 2023Article
- Malnutrition with Low Muscle Mass Is Common after Weaning off Home Parenteral Nutrition for Chronic Intestinal Failure.Nutrients · 2023Article
- Article
- Teduglutide in short bowel syndrome patients: A way back to normal life?JPEN. Journal of parenteral and enteral nutrition · 2022Article
- Intestinal Biopsies for the Evaluation of Environmental Enteropathy and Environmental Enteric Dysfunction.The Journal of infectious diseases · 2021Review
- Proglucagon-Derived Peptides as Therapeutics.Frontiers in endocrinology · 2021Review
- Why Recycling Matters: Glucagon-Like Peptide-2 and the Regulation of Intestinal Sodium and Fluid Absorption.Digestive diseases and sciences · 2020Article
- Controversy in Nutrition Recommendations for Short Bowel Syndrome: How Type of SBS Impacts Response.Current gastroenterology reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 12 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn phase III clinical studies, treatment with teduglutide was associated with clinically meaningful reductions (≥20% from baseline) in parenteral support (PS; parenteral nutrition and/or intravenous fluids) requirements in adult patients with intestinal failure associated with short bowel syndrome (SBS-IF). This analysis reports clinical characteristics of patients who achieved complete independence from PS during teduglutide treatment. MATERIALS AND
methodsPost hoc analysis of adult patients who achieved complete PS independence during treatment with teduglutide 0.05 mg/kg/d. Data were pooled from 5 teduglutide clinical trials (2 phase III placebo-controlled trials [NCT00081458 and NCT00798967] and their respective extension studies [NCT00172185, NCT00930644, NCT01560403]). Descriptive statistics were used; no between-group comparisons were performed because of the small sample size and lack of comparator.
resultsOf 134 patients, 16 gained oral or enteral autonomy after a median of 5 years of PS dependence and 89 weeks of teduglutide treatment. Demographic and baseline disease characteristics varied among patients (median age, 55 years; 50% men; median baseline PS volume, 5.1 L/wk; median residual small intestine length, 52.5 cm). Most patients who achieved PS independence had colon-in-continuity; however, there was no significant difference in the frequency of PS independence among patients who maintained colon-in-continuity vs those who did not.
conclusionFindings from this post hoc analysis suggest that oral or enteral autonomy is possible for some patients with SBS-IF who are treated with teduglutide, regardless of baseline characteristics and despite long-term PS dependence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.